Thyrocare Technologies Ltd.
NSE: THYROCARE · Healthcare Service Provider
Snapshot
Unlock Thyrocare Technologies Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Thyrocare Technologies Limited is an Indian diagnostic and preventive care company providing a wide range of medical testing services to patients, hospitals, and laboratories. It operates through diagnostic testing, imaging services, and other healthcare-related segments, notably leveraging its Aarogyam brand for wellness profiles.
Business Model
The company generates revenue primarily through the provision of diagnostic testing services, the sale of medical consumables, and the distribution of radiopharmaceuticals. It operates a hub-and-spoke model to provide cost-effective, high-volume testing across India.
- Founded:1996
Growth Outlook
Growth is driven by the expansion of the Aarogyam wellness brand and the increasing demand for preventive healthcare services in India. The company continues to focus on scaling its diagnostic network and diversifying its product offerings in the medical consumables space.
Key Risks
- Regulatory Compliance. The diagnostic industry is subject to stringent healthcare regulations and quality standards that may impact operational costs if compliance requirements change.
- Market Competition. The company faces intense competition from both large diagnostic chains and local unorganised players, which may exert pressure on pricing and margins.
- Technological Obsolescence. Failure to keep pace with advancements in diagnostic technology and automation could lead to a loss of market share and operational efficiency.
- Dependency on Referral Networks. The business model relies heavily on a network of laboratories and hospitals, making it vulnerable to shifts in partnerships or referral patterns.
Start your research today
Unlock AI insights, financials, peers and live data on Thyrocare Technologies Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹876 Cr
TTM · consolidated
NET PROFIT
₹176 Cr
TTM · consolidated
EPS
₹17.09
TTM · consolidated
RETURN ON EQUITY
31.1%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
38.4%
TTM · consolidated
P/E
33.7x
Q1 FY27 · consolidated
EV/EBITDA
30.6x
Q1 FY27 · consolidated
EBITDA MARGIN
34.0%
TTM · consolidated
NET PROFIT MARGIN
21.4%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.0x
Q1 FY27 · consolidated
Peers · Healthcare Service Provider
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Thyrocare Technologies Ltd.THYROCARE | ₹9,170 Cr | 33.71 | 30.64 | 21.1% | 34.0% | 31.1% | 38.4% | -57.0% |
Vijaya Diagnostic Centre Ltd.VIJAYA | ₹15,365 Cr | 81.91 | 39.89 | 20.2% | 44.8% | 21.4% | 23.1% | +37.1% |
Metropolis Healthcare Ltd.METROPOLIS | ₹12,205 Cr | 25.21 | 27.32 | 21.8% | 26.0% | 14.3% | 17.8% | -73.7% |
Nephrocare Health ServicesNEPHROPLUS | ₹6,994 Cr | — | — | — | 23.0% | — | — | — |
Krsnaa Diagnostics Ltd.KRSNAA | ₹1,817 Cr | 18.63 | 8.75 | 10.2% | 32.5% | 10.5% | 13.3% | -32.6% |
Suraksha Diagnostic Ltd.SURAKSHA | ₹1,731 Cr | 47.49 | 16.34 | 22.5% | 32.7% | 15.8% | 18.6% | +9.8% |
As of Q1 FY27
Financials
Thyrocare Technologies Ltd.
NSE: THYROCARE · Healthcare Service Provider
Snapshot
Unlock Thyrocare Technologies Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Thyrocare Technologies Limited is an Indian diagnostic and preventive care company providing a wide range of medical testing services to patients, hospitals, and laboratories. It operates through diagnostic testing, imaging services, and other healthcare-related segments, notably leveraging its Aarogyam brand for wellness profiles.
Business Model
The company generates revenue primarily through the provision of diagnostic testing services, the sale of medical consumables, and the distribution of radiopharmaceuticals. It operates a hub-and-spoke model to provide cost-effective, high-volume testing across India.
- Founded:1996
Growth Outlook
Growth is driven by the expansion of the Aarogyam wellness brand and the increasing demand for preventive healthcare services in India. The company continues to focus on scaling its diagnostic network and diversifying its product offerings in the medical consumables space.
Key Risks
- Regulatory Compliance. The diagnostic industry is subject to stringent healthcare regulations and quality standards that may impact operational costs if compliance requirements change.
- Market Competition. The company faces intense competition from both large diagnostic chains and local unorganised players, which may exert pressure on pricing and margins.
- Technological Obsolescence. Failure to keep pace with advancements in diagnostic technology and automation could lead to a loss of market share and operational efficiency.
- Dependency on Referral Networks. The business model relies heavily on a network of laboratories and hospitals, making it vulnerable to shifts in partnerships or referral patterns.
Start your research today
Unlock AI insights, financials, peers and live data on Thyrocare Technologies Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹876 Cr
TTM · consolidated
NET PROFIT
₹176 Cr
TTM · consolidated
EPS
₹17.09
TTM · consolidated
RETURN ON EQUITY
31.1%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
38.4%
TTM · consolidated
P/E
33.7x
Q1 FY27 · consolidated
EV/EBITDA
30.6x
Q1 FY27 · consolidated
EBITDA MARGIN
34.0%
TTM · consolidated
NET PROFIT MARGIN
21.4%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.0x
Q1 FY27 · consolidated
Peers · Healthcare Service Provider
As of Q1 FY27